Answers are grounded in this paper and cite their sources.
Background Biomarkers may show strong outcome associations without adding information to detailed electronic health record (EHR) models. We developed a reproducible benchmark separating association from incremental value for the lactate-to-albumin ratio (LAR) and troponin in older high-acuity patients, with the aim of locating where marker-specific information remains distinct after an information-rich baseline. Methods From 12,000 records in the official CinC 2012 Sets A, B, and C, we included 1,640 patients aged at least 65 years with computable LAR. First-48-h measurements from 37 raw variables produced a transparent 290-feature baseline. Baseline, LAR-augmented, missingness-aware troponin, integrated, and score-enhanced models used L2-regularized logistic regression, random forest, and gradient boosting. Set A supported development, Set B validation and recalibration, and Set C locked internal testing. Evaluation combined discrimination, calibration, paired bootstrap ablation, optimism correction, decision curves, permutation importance, and risk concentration. Results Mortality rose from 18.2% in the lowest LAR max quartile to 36.7% in the highest, with 2.60-fold higher odds of death. The association pointed in the same direction across four ICU categories (odds ratios per stratum-specific LAR interquartile range, 1.30–1.76). The score-enhanced random forest achieved the highest Set C AUROC (0.769; 95% CI: 0.729–0.809). Recalibration improved its Brier score from 0.200 to 0.170 and moved calibration-in-the-large from − 0.652 to 0.078, thereby reducing average overprediction. Paired-bootstrap intervals for LAR or troponin augmentation crossed zero, locating an information-saturation boundary after the 290-feature EHR baseline; decision-curve mean net benefits for baseline and LAR-augmented gradient boosting were 0.120 and 0.122. Troponin-tested patients had higher mortality than untested patients (31.6% vs. 23.6%). Conclusion The benchmark locates where marker value resides: LAR retained a cross-ICU mortality signal while the 290-feature EHR baseline captured most overlapping information; missingness-aware troponin modeling quantified assay values and selective testing. The reusable design distinguishes association, incremental information, probability reliability, and threshold utility. CinC 2012 provides a fixed reproducibility anchor, with contemporary assays and care pathways as the next validation setting.
No takes yet. Share an insight, caveat, or question.
Ni et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: